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Abstract The LLC-PKI cells stably transfected with a rat 
PEPT1 cDNA transported ceftibuten (anion) and cephradine 
(zwitterion), both oral ~-Iactam antibiotics, in a H+-gradient - 
dependent manner. Diethylpyrocarbonate, a histidine residue 
modifier, abolished ceftibuten uptake. This inhibition was 
prevented in the presence of glycylsarcosine or cephradine. 
When expressed in Xenopus oocytes, replacement of either 
histidine 57 or histidine 121 of the rat PEPTI with glutamine by 
site-directed mutagenesis el iminated ceft ibuten and 
[14C]glycylsarcosine transport activities. Immunostaining of 
oocyte sections indicated that insertion of the mutant transpor- 
ters in the plasma membranes was not impaired. These findings 
suggest that both histidine 57 and histidine 121, which are 
conserved in the rat, rabbit and human PEPT1, are involved in 
substrate recognition of this molecule. 
Key words." Proton-coupled peptide transporter; Intestinal 
absorption; [3-Lactam antibiotics; Mutagenesis; Xenopus 
oocyte; Rat intestine 
I. Introduction 
Absorption of oligopeptides in the intestinal epithelial cells 
are mediated by a peptide transport system localized in the 
brush-border membranes [1,2]. Using purified intestinal 
brush-border membrane vesicles, the peptide transport system 
was suggested to be an electrogenic and H+-gradient-driven 
cotransporter [3,4]. Interestingly, the peptide transporter has 
been suggested to serve as a carrier protein for intestinal ab- 
sorption of a broad range of pharmacologically active pep- 
tide-like drugs. For example, oral [3-1actam antibiotics [5 12], 
the antineoplastic agent bestatin [13] and angiotensin-convert- 
ing enzyme inhibitors [14,15] are recognized by the intestinal 
peptide transporter. 
Recently, the H+-coupled oligopeptide transporter PEPT1 
has been cloned from rabbit [16] and human [17]. Ganapathy 
et al. [18] reported differential recognition of I]-lactam anti- 
biotics by human PEPT1 and PEPT2, another member of H + /
peptide transporter family specifically expressed in the kidney 
[19]. The biophysical and kinetic characterization of H+-oli -
gopeptide cotransport mediated by the human PEPTI were 
reported in detail previously [20]. We also cloned and func- 
tionally expressed rat PEPT1 [21] and PEPT2 [22] in Xenopus 
oocytes, and found the localization of rat PEPT1 in the brush- 
border membranes of the small intestine [23]. When expressed 
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in oocytes, the rat PEPT1 transported not only amino-13-1ac- 
tams bearing structural similarity with native oligopeptides, 
but also anionic cephalosporin lacking an c~-amino group 
such as ceftibuten [21]. The rat PEPT1 showed much higher 
affinity for ceftibuten than cephradine in the presence of an 
inward H + gradient [21]. To understand the molecular me- 
chanisms involved in such multispecificity of PEPT1, it is 
necessary to define substrate binding and/or recognition sites 
located in the transporter protein. We report here the residues 
essential for substrate recognition by the PEPT1 transporter 
based on transfection and site-directed mutagenesis. 
2. Materials and methods 
2. I. Cell culture and transfection 
The parental LLC-PK1 cells obtained from the American Type 
Culture Collection (ATCC CRL-1392) were cultured in complete 
medium consisting of Dulbecco's modified Eagle's medium (GIBCO, 
Life Technologies, Grand Island, NY), supplemented with 10% fetal 
bovine serum (Whittaker Bioproducts Inc., Walkersville, MD) with- 
out antibiotics in an atmosphere of 5% CO2-95% air at 37°C [24]. The 
LLC-PK1 cells at 219th passage were used for transfection. The 
cDNA encoding rat PEPTI was subcloned into the Sail- and NotI- 
cut mammalian expression vector pBK-CMV (Stratagene, La Jolla, 
CA) [25]. LLC-PK1 cells were plated at 3)<106 cells per 100-mm 
plastic dishes 24 h before transfection. For transfection, DNA-calcium 
phosphate precipitate formed with 10 lag of pBK-CMV with or with- 
out the rat PEPTI cDNA inserted was added to the cells and incu- 
bated at 37°C. Fifteen hours after transfection, cells were rinsed twice 
with Ca 2+- and Mge+-free Dulbecco's phosphate-buffered saline (pH 
7.4) [PBS ( - )  buffer; (in mM) 137 NaC1, 3 KCI, 8 Na2HPO4 and 1.5 
KH2PO1]. Then, 3 ml of PBS ( - )  containing 15% glycerol was added 
to the cells followed by incubation for 5 min at room temperature. 
Alter washing once with PBS (--), the cells were cultured under nor- 
mal conditions. Forty-eight hours later, the cells were split at dilution 
of 1:75, 1:30 and 1:15. Twelve hours after splitting, G418 (1 mg/ml) 
was added to the culture medium. The medium was replaced with 
fresh medium containing G418 (l mg/ml) every 3 days. Between 14 
and 21 days, single colonies appeared and were picked up for subse- 
quent screening. The G418-resistant clonal cells were grown to con- 
fluence as monolayers on 100-mm dishes. The cells were washed twice 
with PBS (--) and 1 ml of homogenization buffer (10 mM Tris-HCl, 
pit 7.5, 250 mM sucrose, 1 mM EDTA, 0.5 mM phenylmethylsulfo- 
nyl fluoride (PMSF)) was added. After centrifugation (320 x g, 5 min) 
of the scraped cells at 4°C in microfugetubes, the pellets were homo- 
genized with 1 ml of homogenization buffer with a Polytron (Kine- 
matica, Kriens-Luzern, Switzerland) for 1 min. The homogenates were 
centrifuged (320 ×g, 10 min) at 4°C, and the supernatants were recen- 
trifuged (15000xg, 30 min) at 4°C. The pellets consisting of crude 
plasma membrane fractions were suspended in buffer (10 mM Tris- 
HC1, pH 7.5, 250 mM sucrose, 0.5 mM PMSF). The membrane frac- 
tions obtained were analyzed by immunoblotting as described [21]. 
The brush-border membranes from rat duodenum were prepared as 
reported previously [6] and subjected to immunoblotting analysis. 
Abbreviations." Tris, 2-amino-2-(hydroxymethyl)-l,3-propanediol; 
MES, 2-(N-morpholino)ethanesulfonic acid; HEPES, N-2-hydroxy- 
ethylpiperazine-N'-2-ethanesulfonic acid; PMSF, phenylmethylsulfo- 
nyl fluoride; DEPC, diethylpyrocarbonate 
2.2. Uptake studies by cell monolayers 
Uptake of [~-lactam antibiotics was measured in cells grown on 60- 
mm plastic dishes as described previously [12,13]. The protein content 
of cell monolayers solubilized in 1 N NaOH was determined by the 
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method of Bradford [26], using a Bio-Rad Protein Assay Kit (Bio- 
Rad, Richmond, CA) with bovine 7-globulin as a standard. The pro- 
tein content of the monolayers was 1.5 2.0 mg per dish. 
2.3. Site-directed mutagenesis 
The plasmid pSPORT1 (GIBCO) inserted with the rat PEPT1 
cDNA at Sail and NotI sites served as a template for PCR mutagen- 
esis. PCR reactions was carried out under two sets of conditions: T7 
promoter primer and mNOT (5'-GGATCCTCTAGAGCGTCCGC- 
Y), which eliminates the NotI site; and with mutagenic oligonucleo- 
tides and SP6 promoter primer. The mutagenic oligonucleotides u ed 
were as follows (base changes are in italics): 5'-GCCATCTAC- 
CAAACGTTTGT-3', which replaces a histidine residue at position 
57 with glutamine (H57Q); 5'-CTTCCTTTGCAGGTAGCACT-Y, 
which replaces a histidine residue at position 121 with glutamine 
(H121Q). The two amplified products were combined and used as a 
template for second PCR with T7 and SP6 primers. Second PCR 
products containing the mutation possessed Sail and NotI sites. Fol- 
lowing digestion by Sail and NotI, the fragments were directionally 
ligated into Sail- and NotI-cut pSPORT1. Double mutation (H57Q 
and H121Q) was constructed under the same conditions as described 
above with the H121Q mutant as a template. All the mutations were 
confirmed by sequence analysis with Sequenase version 2.0 (United 
States Biochemical, Cleveland, OH) or Ampli Taq DNA polymerase 
(Perkin Elmer Applied Biosystems Division, Foster City, CA). 
2.4. Expression in Xenopus oocytes 
Twenty-ng aliquots of capped complementary RNA (cRNA) tran- 
scribed in vitro from NotI-linearized wild-type and mutant PEPT1 
cDNA using T7 RNA polymerase were injected into Xenopus oocytes. 
Injected oocytes were maintained in modified Barth's medium at 18°C 
for 24-48 hours. Functional expression of the wild-type and mutant 
PEPT1 was assessed by measuring uptake of ceftibuten or 
[lIC]glycylsarcosine in groups of oocytes injected with 50 nl of water 
or cRNA as described previously [21]. Groups of 10 injected oocytes 
from the uptake experiments were prepared for immunostaining. 
Briefly, the oocytes were fixed in 3% paraformaldehyde at 4°C /or 
1 h and immersed in PBS (--) containing 30% sucrose at 4°C for 
18 h. The fixed oocytes were embedded in O.C.T. compound (Miles 
Diagnostic Division, Elkhart, IN) and frozen at -20°C. Sections (8 
I.tm thick) were cut, dried on glass slides, and washed with PBS (-).  
The sections were then covered with 10% normal goat serum (GIB- 
CO) for 10 min, and incubated with anti-rat PEPT1 serum (1:100 
dilution) at 4°C for 12 h. After washing with PBS (-),  the sections 
were incubated with FITC-labeled goat anti-rabbit IgG (5 ~tg/ml, 
GIBCO) at 37°C for 30 min, and then washed again with PBS (-).  
The specimens were mounted in 11% glycerol in 56 mM Tris-HCl 
buffer (pH 9.0) containing 5% 1,4-diazabicyclo[2,2,2]octane (DABCO) 
as an anti-bleaching reagent. The sections were examined under an 
Olympus BX-50 microscope and photographed with an Olympus PM- 
30 microscope camera. 
2.5. Materials 
Ceftibuten (Shionogi and Co., Osaka, Japan) and cephradine (San- 
kyo Co., Tokyo, Japan) were gifts from the respective suppliers. 
[14C]Glycylsarcosine (1.78 GBq/mmol) was obtained from Daiichi 
Pure Chemicals Co., Ltd. (Ibaraki, Japan). Glycylsarcosine was ob- 
tained from Sigma Chemical Co. (St. Louis, MO). Glycine and DEPC 
were purchased from Nacalai Tesque Inc. (Kyoto, Japan). All other 
chemicals used were of the highest purity available. 
3. Results 
The pBK-CMV vector with or without the rat PEPT1 
cDNA inserted was transfected into LLC-PK1 cells as de- 
scribed in Section 2. The membrane fractions isolated from 
G418-resistant cells were examined by immunoblotting using 
antiserum for rat PEPT1 [21,23]. LLC-PK1 cells transfected 
with the rat PEPT1 cDNA (LLC-rPEPT1) expressed a novel 
protein with the apparent molecular mass of ,~ 75 kDa, which 
was consistent with the protein found in the purified brush- 
border membranes of the rat duodenum (Fig. 1). On the other 
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Fig. 1. Western blot analysis of crude membranes i olated from 
LLC-rPEPT1 and LLC-pBK, and of brush-border membranes puri- 
fied from rat duodenum. Membrane proteins were separated by 
SDS-polyacrylamide g l (10%) electrophoresis and blotted to polyvi- 
nylidene difluoride membranes. The antiserum for rat PEPT1 [21] 
(1:1000 dilution) was used as primary antibody. A peroxidase-conju- 
gated anti-rabbit IgG antibody was used for detection of bound 
antibodies, and strips of the blots were visualized by chemilumines- 
cence on X-ray film. The arrow indicates the position of PEPT1. 
hand, LLC-PK1 cells transfected with the control vector 
(LLC-pBK) showed no immunoreactive protein. 
Using the LLC-rPEPT1 cells, uptake of cephalosporins was 
examined. As illustrated in Fig. 2A, uptake of ceftibuten (an 
anionic cephalosporin lacking an m-amino group) was mark- 
edly stimulated by lowering pH of the medium, but uptake of 
cephradine (a zwitterionic aminocephalosporin) was maximal 
at pH 5.5-6.0 (Fig. 2B). The uptake rates of both drugs by 
LLC-pBK cells were markedly lower than that by LLC- 
rPEPT1 cells and remained unaffected by pH. 
Previously, we reported that histidine residues are involved 
in the transport activity of the peptide transport system in 
purified brush-border membrane vesicles from the rabbit 
small intestine [27]. The inactivation of transport by DEPC, 
a histidine modifier, was abolished in the presence of cephra- 
dine or glycylsarcosine, suggesting that histidine residues in 
the transporter are essential for its substrate recognition. 
Therefore, we examined the effect of DEPC on ceftibuten 
uptake by LLC-rPEPT1 cells. As shown in Fig. 3, ceftibuten 
uptake was markedly inhibited by pretreatment with DEPC (1 
mM) at 25°C. This inhibition was also found at 4°C (data not 
shown). Glycylsarcosine and cephradine, but not glycine, 
completely abolished the inhibitory effect of DEPC, suggest- 
ing that histidine residues are involved in the interaction of 
dipeptides or [3-1actam antibiotics with the transporter. Pre- 
treatment with either glycylsarcosine or cephradine in the ab- 
sence of DEPC showed no inhibitory effect on ceftibuten up- 
take. In a separate xperiment, [14C]glycylsarcosine (20 p.M) 
uptake by LLC-rPEPT1 cells was also completely inhibited by 
the DEPC pretreatment (control, 827+38; DEPC, 49+2,  
pmol/mg protein/15 min, mean + S.E. of three monolayers). 
The inhibitory effect of DEPC on the [14C]glycylsarcosine up- 
take was almost prevented by 10 mM cephradine but not by 
10 mM ceftibuten (cephradine, 771; ceftibuten, 53, pmol/mg 
protein/15 min, mean of two monolayers). 
The PEPT1 transporter is predicted to possess 12 trans- 
membrane ~x-helices [16,17,21]. We assumed that histidine 
residues located in the putative transmembrane ~x-helices 
play an important role in substrate binding. Seven histidine 
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Fig. 2. The pH-dependence of ceftibuten (A) and cephradine (B) up- 
take by LLC-rPEPT1 and LLC-pBK cells. LLC-rPEPTI cells (O) or 
LLC-pBK cells (©) were incubated for 60 min at 37°C with 1 mM 
ceftibuten or cephradine at various pH values. After incubation, cel- 
lular uptake of drugs was measured. Each point represents he 
mean_+ S.E. of three independent monolayers. When the error bar is 
not shown, it is smaller than the symbol. 
residues are conserved among rat [21], rabbit [16] and human 
[17] PEPT1. Among these residues, histidine 57 and histidine 
121, which are located in the predicted transmembrane c~- 
helices 2 and 4, respectively, were of special interest. There- 
fore, histidine residue 57 or 121, or both, were replaced by 
glutamine using site-directed mutagenesis. After the mutations 
were verified by sequencing, cRNA was synthesized for the 
wild-type and mutant PEPT1 and then injected into Xenopus 
oocytes. As shown in Fig. 4A, injection of wild-type PEPT1 
cRNA stimulated [14C]glycylsarcosine uptake about 3-fold 
above the uptake in water-injected oocytes. The uptake of 
[14C]glycylsarcosine was completely abolished in the oocytes 
injected with cRNA of either histidine 57 mutant (H57Q) or 
histidine 121 mutant (H121Q), or histidine 57 and 121 double 
mutant (H57Q/H121Q). The wild-type PEPTI also stimulated 
the uptake of ceftibuten about 5-fold above the water-injected 
control value as observed previously [21], and H+-gradient - 
dependent transport activity of ceftibuten was not found in 
any of the oocytes injected with the mutant cRNA (Fig. 4B). 
One possible reason for defective transport activity of these 
histidine mutants is decreased level of the mutant protein in 
the oocyte plasma membranes, which could be caused by re- 
duced stability and/or impaired insertion to the membranes of
the mutants. To examine this possibility, immunolocalization 
of the PEPT1 mutants in the oocytes was performed. As 
shown in Fig. 5, oocytes expressing the wild-type PEPT1 
and all of the histidine mutants, H57Q, H121Q and double 
mutant, displayed a strong bright ring along the plasma mem- 
branes, whereas native oocytes (no injection) or those injected 
with water exhibited no labeling of the membranes. 
4. Discussion 
Recent molecular approaches have revealed that two struc- 
turally different H+-coupled peptide transporters are localized 
in the intestine and kidney: PEPT1 is expressed primarily in 
the small intestine and to a lesser extent in the kidney 
[16,17,21], whereas the PEPT2 is expressed specifically in the 
kidney [19,22,28]. These transporters exhibit about 50% ami- 
no acid identity. Expression of the rabbit PEPT1 in Xenopus 
oocytes and of the human PEPT1 exhibited the electrogenic 
and H+-gradient-driven glycylsarcosine transport [16,17]. The 
rabbit PEPT1 showed high apparent affinity for the anionic 
dipeptide alanyl-aspartate compared to other neutral or posi- 
tively charged dipeptides [16]. When expressed in Xenopus 
oocytes, the rat PEPT1 accepted both ceftibuten, an anionic 
cephalosporin lacking an s-amino group, and cephradine, a 
neutral aminocephalosporin [21]. The PEPT1 appears to me- 
diate translocation of these oral antibiotics regardless of the 
presence of an c~-amino group in their molecules, and to pre- 
fer anionic species as substrates. 
In the present study, we established a stable renal epithelial 
cell line transfected with the rat PEPT1 cDNA, LLC-rPEPT1, 
which expressed the ,-, 75 kDa PEPTI protein as detected by 
immunoblotting with anti-rat PEPT1 antiserum (Fig. 1). Most 
importantly, pH profiles of the uptake of ceftibuten and ce- 
phradine by LLC-rPEPT1 cells (Fig. 2) were consistent with 
those found in both brush-border membrane vesicles [8,29] 
and Caco-2 cells [11,12]. Ceftibuten bears two carboxyl 
groups (pK~=2.3 and 3.2) and one aminothiazole group 
(pK~=4.5), and cephradine has one carboxyl group 
(pK~ = 2.6) and one amino group (pK~ = 7.4). Therefore, ionic 
species of both drugs are different in the range of pH 5.0 7.4, 
namely ceftibuten and cephradine exist mostly in the form of 
an anion and zwitterion, respectively. Therefore, the marked 
differences in their pH profiles cannot be explained simply by 
the changes in ionic species of each drug over the pH range 
examined. If charged amino acid residues are present in the 
substrate binding sites of rat PEPT1, affinity of the transpor- 
ter for charged substrates might be affected by environmental 
pH, thereby exhibiting such differences in dependence on pH. 
To investigate involvement of charged amino acid residues 
in substrate recognition by rat PEPT1, site-directed mutagen- 
esis was performed. Mutations at histidine 57 and histidine 
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121 were of special interest, because these residues are located 
in the predicted transmembrane c~-helices and are highly con- 
served in all PEPT1 examined to date [16,17,21]. Replacement 
of each histidine residue by glutamine resulted in elimination 
of the PEPT1 transport activity when expressed in oocytes. 
This defective activity was not caused by the insufficient ar- 
geting of the transporter into the plasma membranes, because 
these mutants still produced levels of the transporter similar 
to those of wild-type PEPT1. Therefore, both histidine 57 and 
histidine 121 were defined to be localized in substrate binding 
site and/or to be involved in intrinsic transport activity of 
PEPT1. The protection of DEPC-induced inactivation of cef- 
tibuten transport by glycylsarcosine or cephradine (Fig. 3) 
suggests that these conserved histidine residues are involved 
in the interaction of substrates with recognition sites of the 
transporter. Previously, we reported that histidine residues of 
the peptide transporter play an important role in transport of 
13-1actam antibiotics by using DEPC-inactivated intestinal 
brush-border membrane vesicles [27]. In the present study, it 
is noteworthy that cephradine but not ceftibuten prevented 
the DEPC-induced inactivation of glycylsarcosine transport, 
suggesting differences in the ability of differently charged 13- 
lactams to protect the PEPT1 from modification by DEPC. 
Surprisingly, the corresponding histidine residues are also 
conserved in the putative membrane-spanning c~-helices of 
PEPT2 from the human [19], rabbit [28] and rat [22] kidney. 
Miyamoto et al. [30] also reported that essential histidine 
residues might be present at the dipeptide-binding site of the 
rabbit renal dipeptide transporter. Further studies using site- 
directed mutagenesis of PEPT2 will provide additional infor- 
mation regarding the roles of these highly conserved histidine 
residues in substrate recognition by the peptide transporter 
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Fig. 3. Effects of DEPC pretreatment on ceftibuten uptake by LLC- 
rPEPT1 cells. LLC-rPEPTI cells were preincubated at 25°C for 10 
min with 1 mM DEPC (pH 6.0) in the absence or presence of gly- 
cylsarcosine, cephradine or glycine at 10 mM. After preincubation, 
LLC-rPEPTI cells were rinsed once with incubation medium with- 
out drug and then incubated with ceftibuten (1 mM, pH 6.0) for 60 
min at 37°C. After incubation, cellular uptake of ceftibuten was 
measured. Each column represents the mean+S.E, of three inde- 
pendent monolayers. GLY-SAR, glycylsarcosine; CED, cephradine; 
GLY, glycine. 
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Fig. 4. [14C]Glycylsarcosine (A) and ceftibuten (B) uptake by oo- 
cytes expressing wild-type and histidine mutant rat PEPTh Uptake 
by oocytes was assayed for 1 or 2 h at 25°C in the presence of 
either [14C]glycylsarcosine (20 laM, 37 kBq/ml) or ceftibuten (1 mM) 
2448 h after injection of 50 nl of water or cRNA (20 ng). 
[14C]Glycylsarcosine and ceftibuten taken up by oocytes were meas- 
ured as described previously [21,22]. Each column represents the 
mean _+ S.E. of 3 5 experiments. Three ([14C]glycylsarcosine uptake) 
or four (ceftibuten uptake) oocytes were used for each uptake ex- 
periment. H57Q, histidine 57 --* glutamine; H121Q, histidine 121 
glutamine; H57Q/H121Q, histidines 57 and 121 -~ glutamine 
(double mutant). 
family. The possibility that these conserved histidines play 
an important role in the translocation of H + cannot be ex- 
cluded because PEPT1 transporters are coupled with H +. Re- 
cently, Mackenzie et al. [20] reported that glycylsarcosine 
evoked voltage- and H+-dependent currents in oocytes expres- 
sing human PEPT1, and proposed that H + behaves as an 
essential activator of oligopeptide transport, suggesting an 
ordered transport model in which H + binds first. Histidine 
200 
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Fig. 5. Expression of wild-type and histidine mutant PEPTI transporter proteins in oocytes. Oocytes were injected with 50 nl of water or 
cRNA (20 ng) of wild-type or mutant rat PEPT1. Two days after injection, oocytes were fixed, frozen, sectioned, and stained as described in 
Section 2. The antiserum (1:100 dilution) for rat PEPTI was used as the primary antibody. FITC-labeled goat anti-rabbit IgG (5 lag/ml) was 
used for detection of bound antibodies. Abbreviation for each mutant is the same as described in Fig. 4. 
57 and histidine 121 in the PEPT1 protein might serve as 
proton acceptors. It is very likely that other residues located 
in transmembrane s gments 2 and 4 participate in the trans- 
port mechanisms. 
In summary, we stably transfected the rat PEPT1 transpor- 
ter cDNA into LLC-PK1 kidney epithelial cells, and showed 
that histidine residues were essential for cephalosporin trans- 
port. Site-directed mutagenesis suggested that histidine 57 and 
histidine 121 in the predicted transmembrane domains 2 and 
4, respectively, are involved in substrate binding and/or re- 
sponsible for intrinsic activity of the transporter. These pres- 
ent findings provide valuable insight into transport mecha- 
nisms and structure-function relationships of this transporter 
family, as well as into drug design to improve intestinal ab- 
sorption. 
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